# Beacon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beacon-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.beacontx.com
- Total disclosed funding: $365M
- Latest round: Series C (Dec 29, 2025)
- Investors on record: 7

## About

Based in London, UK, and founded in 2023, Beacon Therapeutics Limited, formerly known as Alliance Holdco Limited, operates as an ophthalmic gene therapy company that develops treatments for eye diseases. In December 2025, Beacon Therapeutics Limited raised USD 75 million in series C funding led by Goldman Sachs Asset Management, with participation from Retinal Degeneration Fund, Advent Life Sciences, Oxford Sciences Enterprises, Forbion, and Syncona.

The company works on the development of gene therapy to restore and improve the vision of patients suffering from various prevalent and rare retinal diseases that lead to blindness. Beacon Therapeutics combines a late-stage development candidate for X-linked retinitis pigmentosa (XLRP) with two innovative preclinical programs targeting prevalent and rare blinding diseases. Their gene therapy approach involves modifying a patient's cells by introducing a functional copy of the mutated gene responsible for the disease, allowing the body to produce the necessary proteins to treat or prevent the genetic condition. As of June 2023, Beacon Therapeutics has a diverse pipeline, including a Phase 2 clinical trial for their lead development candidate, AGTC-501, designed to treat XLRP. Additionally, the firm is developing preclinical programs for dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD), both of which are inherited retinal diseases.

The company plans to utilize its December 2025 funding to advance laru-zova toward commercialization for X-linked retinitis pigmentosa and accelerate development of additional pipeline candidates.

## Funding rounds

- Series C, Dec 29, 2025, $75M — Forbion, Goldman Sachs Asset Management, Syncona, Oxford Sciences Enterprises, Advent Life Sciences, Retinal Degeneration Fund
- Series B, Jul 3, 2024, $169M — Forbion, Syncona, Oxford Sciences Enterprises, Advent Life Sciences, TCG Crossover Management
- Series A, Jun 12, 2023, $121M — Syncona, Oxford Sciences Enterprises

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B, Series C
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A, Series B, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series C
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B, Series C
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series C